COMBINED USE OF ENZYME INHIBITORS AND PHARMACEUTICAL PREPARATIONS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF ARTERIOSCLEROSIS, FOR THE TREATMENT AND PREVENTION OF ALLERGIC REACTIONS OF TYPE I ACCORDING TO THE GELL AND COOMBS CLASSIFICATION, AND FOR THE TREATMENT AND PREVENTION OF DERMATOLOGICAL DISEASES ASSOCIATED WITH FO

摘要

The invention relates to the use of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same specific nature of substrate (DP IV enzyme activity), combined with inhibitors of alanyl aminopeptidase (aminopeptidase N, APN), or enzymes having the same specific nature of substrate (APN enzyme activity), for the additive to superadditive inhibition of the activation and proliferation (DNS synthesis) of human T lymphocytes or mononuclear cells and of the production of TH2 cytokines for the treatment and prevention of allergic reactions of type I according to the Gell and Coombs classification, for the additive to superadditive inhibition of the activation and proliferation (DNS synthesis) of human epidermal and follicular keratinocytes and those of the transitional region between the skin and the mucosa, and for the treatment and prevention of dermatological diseases associated with follicular and epidermal hyperkeratosis and reinforced keratinocyte proliferation. The invention also relates to the use of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same specific nature of substrate (DP IV enzyme activity), combined with inhibitors of alanyl aminopeptidase (aminopeptidase N, APN), or enzymes having the same specific nature of substrate (APN enzyme activity), inhibitors of X-pro-aminopeptidase (aminopeptidase P, APP), inhibitors of the angiotensin-converting enzyme (ACE) and/or of prolyoligopeptidase (POP, prolylendopeptidase, PEP) for the additive to superadditive inhibition of the activation, DNS synthesis and proliferation of human T lymphocytes or mononuclear cells for the treatment and prophylaxis of arteriosclerosis. The invention further relates to pharmaceutical preparations comprising a plurality of inhibitors of enzymes of the above-mentioned groups.